<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dias MH</submitter><funding>CERCA Program/Generalitat de Catalunya</funding><funding>European Research Council</funding><funding>Instituto de Salud Carlos III</funding><funding>Sao Paolo Research Foundation</funding><funding>Shanghai Academic/Technology Research Leader</funding><funding>National Natural Science Foundation of China</funding><funding>Instituto de Salud Carlos III (ISCIII)</funding><funding>National Natural Science Foundation of China (NSFC)</funding><funding>São Paulo State Foundation-FAPESP: CeTICS-Grant</funding><pagination>1276-1301</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11215412</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(7)</volume><pubmed_abstract>Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also </pubmed_abstract><journal>Cancer discovery</journal><pubmed_title>Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.</pubmed_title><pmcid>PMC11215412</pmcid><funding_grant_id>PI19-01320 and PI22-00548</funding_grant_id><funding_grant_id>2019/10753-2</funding_grant_id><funding_grant_id>2013/07467-1</funding_grant_id><funding_grant_id>2017SGR449 and 2021 SGR 00184</funding_grant_id><funding_grant_id>2020/10277-3</funding_grant_id><funding_grant_id>FI20/00130</funding_grant_id><funding_grant_id>grant 82222047</funding_grant_id><funding_grant_id>787925</funding_grant_id><funding_grant_id>22XD1423100</funding_grant_id><pubmed_authors>Morris B</pubmed_authors><pubmed_authors>Dekker A</pubmed_authors><pubmed_authors>Medema RH</pubmed_authors><pubmed_authors>Mainardi S</pubmed_authors><pubmed_authors>Qin W</pubmed_authors><pubmed_authors>Armelin HA</pubmed_authors><pubmed_authors>Mulero-Sanchez A</pubmed_authors><pubmed_authors>Lieftink C</pubmed_authors><pubmed_authors>Vidal A</pubmed_authors><pubmed_authors>Bernards R</pubmed_authors><pubmed_authors>Kuiken HJ</pubmed_authors><pubmed_authors>Jin H</pubmed_authors><pubmed_authors>Beijersbergen RL</pubmed_authors><pubmed_authors>Salazar R</pubmed_authors><pubmed_authors>Snaebjornsson P</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>da Silva MS</pubmed_authors><pubmed_authors>van Oudenaarden A</pubmed_authors><pubmed_authors>Villanueva A</pubmed_authors><pubmed_authors>Friskes A</pubmed_authors><pubmed_authors>Yuan S</pubmed_authors><pubmed_authors>Kovach JS</pubmed_authors><pubmed_authors>Dias MH</pubmed_authors><pubmed_authors>Papagianni C</pubmed_authors><pubmed_authors>Wailemann RAM</pubmed_authors><pubmed_authors>Torres TEP</pubmed_authors><pubmed_authors>De Conti G</pubmed_authors><pubmed_authors>Jansen RA</pubmed_authors><pubmed_authors>Te Riele H</pubmed_authors><pubmed_authors>Alvarez-Villanueva D</pubmed_authors><pubmed_authors>van Gemert F</pubmed_authors><pubmed_authors>Raaijmakers JA</pubmed_authors><pubmed_authors>Santos C</pubmed_authors><pubmed_authors>Wilms LHS</pubmed_authors><pubmed_authors>Fernandes Neto JM</pubmed_authors><pubmed_authors>van Dijk E</pubmed_authors><pubmed_authors>Mourragui S</pubmed_authors><pubmed_authors>Malzer E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.</name><description>Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-06-26T03:11:12.814Z</modification><creation>2025-04-07T02:11:21.789Z</creation></dates><accession>S-EPMC11215412</accession><cross_references><pubmed>38533987</pubmed><doi>10.1158/2159-8290.CD-23-0216</doi></cross_references></HashMap>